首页 | 本学科首页   官方微博 | 高级检索  
检索        

涂阳肺结核患者γ-干扰素释放试验假阴性的影响因素分析
引用本文:马进宝,马婷婷,任斐,杨翰,谭淦纹.涂阳肺结核患者γ-干扰素释放试验假阴性的影响因素分析[J].中国防痨通讯,2020,42(12):1299-1304.
作者姓名:马进宝  马婷婷  任斐  杨翰  谭淦纹
作者单位:710100.西安市胸科医院耐药结核科(马进宝、任斐),妇儿结核科(马婷婷),检验科(杨翰),影像科(谭淦汶)
摘    要:目的 分析γ-干扰素释放试验(IGRA)检测痰涂阳肺结核患者出现假阴性结果的影响因素。方法 搜集2019年6—12月就诊于西安市胸科医院的196例痰涂阳肺结核患者作为研究对象,其中,男145例(74.0%),女51例(26.0%);年龄中位数(四分位数)M(Q1,Q3)]为38(26,53)岁。按IGRA检测结果分为IGRA检测阳性组(106例)和假阴性组(90例)。收集研究对象一般资料、临床症状、实验室检验资料,以及胸部CT表现,采用多因素logistic回归分析IGRA检测痰涂阳肺结核患者出现假阴性结果的影响因素。结果 196例研究对象中,IGRA检测阳性106例,阳性率为54.1%。IGRA阳性组白细胞计数的M(Q1,Q3)为6.3(5.0,7.5)×109个/L,低于IGRA假阴性组的7.4(5.8,9.2)×109个/L,差异有统计学意义(Z=-3.464,P=0.001);血红细胞沉降率的M(Q1,Q3)为34.5(16.0,58.0)mm/1h,低于IGRA假阴性组的53.0(31.8,84.3)mm/1h,差异有统计学意义(Z=-3.492,P=0.000);CD4+ T淋巴细胞计数的M(Q1,Q3)为553(371,737)个/μl,高于IGRA假阴性组的432(320,645)个/μl,差异有统计学意义(Z=-2.080,P=0.038)。多因素logistic回归分析显示,白细胞计数≥7.0×109个/LOR(95%CI)=3.003(1.618~5.572)]、ESR≥40mm/1hOR(95%CI)=2.270(1.228~4.195)]、CD4+ T淋巴细胞计数<400 个/μlOR(95%CI)=2.198(1.155~4.181)]是影响IGRA检测痰涂阳肺结核患者出现假阴性结果的独立危险因素。结论 白细胞计数升高、血红细胞沉降率升高、CD4+T淋巴细胞计数降低是IGRA检测涂阳肺结核患者出现假阴性结果的危险因素,临床应用IGRA辅助结核病诊断时需结合患者情况综合分析。

关 键 词:结核    干扰素γ  免疫学试验  危险因素  因素分析  统计学  
收稿时间:2020-04-16

Analysis on risk factors associated with false negative results of interferon-gamma release assay in active tuberculosis
MA Jin-bao,MA Ting-ting,REN Fei,YANG Han,TAN Gan-wen.Analysis on risk factors associated with false negative results of interferon-gamma release assay in active tuberculosis[J].The Journal of The Chinese Antituberculosis Association,2020,42(12):1299-1304.
Authors:MA Jin-bao  MA Ting-ting  REN Fei  YANG Han  TAN Gan-wen
Institution:Department of Drug-resistance tuberculosis, Xi’an Chest Hospital, Xi’an 710100, China
Abstract:Objective To analysis risk factors associated with false negative result of interferon-gamma release assay (IGRA) in pulmonary tuberculosis with positive sputum smear. Methods A total of 196 pulmonary tuberculosis patients with positive sputum smear were collected from June to December 2019 in Xi’an Chest Hospital, including 145 males (74.0%) and 51 females (26.0%); the median age (M(Q1,Q3)) was 38 (26, 53) years. They were divided into IGRA positive group (n=106) and false negative group (n=90). Data of general information, clinical symptoms, results of laboratory test and chest CT findings were collected. Multivariate logistic regression analysis was used to analyze the risk factors associated with false negative result of IGRA in pulmonary tuberculosis patients with positive sputum smear. Results Among the 196 patients, 106 cases were IGRA positive (54.1%). The white blood cell count (M(Q1,Q3)) of IGRA positive group was 6.3 (5.0, 7.5)×109 cells/L, which was statistically lower than that of IGRA false negative group (7.4 (5.8, 9.2)×109 cells/L) (Z=-3.464, P=0.001); the erythrocyte sedimentation rate (M(Q1,Q3)) in IGRA positive group was also statistically lower than that in IGRA false negative group (34.5 (16.0,58.0) mm/1 h vs. 53.0 (31.8, 84.3) mm/1 h, Z=-3.492, P=0.000); however, the number of CD4+T lymphocytes in IGRA positive group was statistically higher than that in IGRA false negative group (553 (371,737) cells/μl vs. 432(320, 645) cells/μl, Z=-2.080, P=0.038). Using multivariate logistic regression analysis, it was showed that white blood cell count ≥7.0×109 cells/L (OR(95%CI)=3.003 (1.618-5.572)), erythrocyte sedimentation rate ≥40mm/1 h (OR(95%CI)=2.270 (1.228-4.195)), CD4+T cell <400 cells/μl (OR(95%CI)=2.198(1.155-4.181)) were dependent risk factors for false negative result of IGRA in pulmonary tuberculosis with positive sputum smear. Conclusion The increase of white blood cell and erythrocyte sedimentation rate, as well as the decrease of CD4 +T cell are dependent factors for false negative result of IGRA, the clinical application of IGRA to aid tuberculosis diagnosis should combine with other factors of patients.
Keywords:Tuberculosis  pulmonary  Interferon-gamma  Immunologic tests  Risk factors  Factor analysis  statistical  
点击此处可从《中国防痨通讯》浏览原始摘要信息
点击此处可从《中国防痨通讯》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号